Generic drugmaker Natco Pharma reported consolidated net profit for the June quarter declined more than 28% to ₹480.3 crore compared to ₹668.5 crore a year earlier amid pricing pressure in the key U.S. market and higher research and development expenditure.

The lower net profit came on a total revenue that dipped 1.42% to ₹1,390.6 crore (₹1,410.7 crore). During the quarter the business faced pricing pressure in the U.S. product portfolio and the company incurred increased R&D expenses on account of high value projects, Natco Pharma said.

₹2 interim dividend

The company has declared an interim dividend of ₹2 per equity share (of ₹2 each) for the first quarter.

Segmental revenue breakup showed formulations export declined, in the first quarter, to ₹1,126.5 crore (₹1,210.1 crore). Revenue from active pharmaceutical ingredients (API) increased to ₹52.6 crore (₹39.2 crore), while that from domestic formulations to ₹107 crore (₹102.2 crore). Crop Health Sciences revenue increased to ₹34.7 crore (₹15.6 crore).

Generic drugmaker and biotech company Laurus Labs reported consolidated net profit for June quarter surged to ₹163 crore from ₹13 crore year earlier.

The higher net profit came on a 31% increase in revenue from operations to ₹1,570 crore (₹1,195 crore). Founder and CEO Satyanarayana Chava attributed the performance to increasing contributions from CDMO business and continued advancement of pipeline projects, supported by Generic FDF.

The company’s shares registered a new 52-week high of ₹845.60 each on Friday (July 25, 2025) before closing less than 1% higher at ₹838.85 apiece on the BSE.

“We are moving ahead with strong focus on commercial execution realising the full potential from promising pipeline opportunities, business development and rapidly enhancing scale and technology capabilities. Construction of various facilities across CDMO, generics and FDF has commenced,” he said.

Revenue breakup showed share of CDMO went up to ₹522 crore (₹257 crore), while contribution of generics increased 12% to ₹1,048 crore (₹938 crore). The company said CDMO growth was driven by several mid-to-late stage NCE deliveries and ramp up from new manufacturing assets. There was sustained demand in high-value and complex small molecule offerings. Bio business reported lower revenue at ₹29 crore (₹43 crore) on impact by customer specific scale-up and scheduling issue. Generics revenue growth was driven by both ARV and developed market portfolio within FDF, Laurus Labs said.